Sepsis Of The Newborn — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for sepsis of the newborn. 7 active patents protecting 2 drugs from 2+ originators. First major cliff: 2035. Daily refresh.

2
Approved drugs
7
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Sepsis Of The Newborn

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

ANI Pharmaceuticals 5 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating sepsis of the newborn. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
28
1
30
5
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vancocin
vancomycin
 ANI Pharmaceuticals 5 39 — 2035-11-06
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
10207066 Tobi method of use 68 2030-11-04
11517609 Vancocin method of use 53 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
10849956 Vancocin formulation 25 2035-11-06
11000567 Vancocin formulation 25 2035-11-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10849956 Vancocin formulation 25 2035-11-06
11000567 Vancocin formulation 25 2035-11-06
10188697 Vancocin method of use 45 2035-11-06
10039804 Vancocin method of use 45 2035-11-06
11517609 Vancocin method of use 53 2035-11-06
10207066 Tobi method of use 68 2030-11-04
8869794 Tobi method of use 75 2028-09-12

Related